Nanobiotix (NASDAQ:NBTX) Shares Climb 5.6% – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s share price traded up 5.6% on Thursday. The stock traded as high as $29.68 and last traded at $28.4170. Approximately 14,048 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 98,940 shares. The stock had previously closed at $26.90.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, October 15th. Guggenheim started coverage on Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $46.67.

View Our Latest Stock Report on NBTX

Nanobiotix Trading Down 3.0%

The stock’s fifty day moving average price is $29.31 and its 200 day moving average price is $34.35.

Institutional Investors Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Aquatic Capital Management LLC bought a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,118 shares of the company’s stock, valued at approximately $66,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.

Further Reading

Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.